Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

V C Jordan

Showing results (361-370 of 365) with videos related to

Pageof 37
Sort By:
You have reached the last page of results.This site can display upto 365 results.
Journal of Immunotherapy : Official Journal of the Society for Biological Therapy|January 1, 1992
Influence of estradiol and tamoxifen on susceptibility of human breast cancer cell lines to lysis by lymphokine-activated killer cellsM R Albertini, D F Gibson, S P Robinson, et al.
Journal of the National Cancer Institute|October 28, 1998
Effects of the antiestrogens tamoxifen, toremifene, and ICI 182,780 on endometrial cancer growthR M O'Regan, A Cisneros, G M England, et al.
JAMA|June 22, 1999
The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene EvaluationS R Cummings, S Eckert, K A Krueger, et al.
Breast Cancer Research and Treatment|March 23, 2001
Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluationJ A Cauley, L Norton, M E Lippman, et al.
Clinical Pharmacology and Therapeutics|September 25, 2013
CYP2D6 genotype and adjuvant tamoxifen: meta-analysis of heterogeneous study populationsM A Province, M P Goetz, H Brauch, et al.
Pageof 37

Showing results (361-370 of 365) with videos related to

Sort By:
Pageof 37
You have reached the last page of results.This site can display upto 365 results.
Journal of Immunotherapy : Official Journal of the Society for Biological Therapy|January 1, 1992
Influence of estradiol and tamoxifen on susceptibility of human breast cancer cell lines to lysis by lymphokine-activated killer cellsM R Albertini, D F Gibson, S P Robinson, et al.
Journal of the National Cancer Institute|October 28, 1998
Effects of the antiestrogens tamoxifen, toremifene, and ICI 182,780 on endometrial cancer growthR M O'Regan, A Cisneros, G M England, et al.
JAMA|June 22, 1999
The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene EvaluationS R Cummings, S Eckert, K A Krueger, et al.
Breast Cancer Research and Treatment|March 23, 2001
Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluationJ A Cauley, L Norton, M E Lippman, et al.
Clinical Pharmacology and Therapeutics|September 25, 2013
CYP2D6 genotype and adjuvant tamoxifen: meta-analysis of heterogeneous study populationsM A Province, M P Goetz, H Brauch, et al.
Pageof 37